Cell Therapy Consumables Market Size, Growth and Forecast 2032

Cell Therapy Consumables Market Overview:

Cell therapy consumables Market was valued at USD 3439 million in 2024 and is anticipated to reach USD 7533.31 million by 2032, growing at a CAGR of 10.3% during the forecast period.

The Cell Therapy Consumables Market is shaped by leading players such as Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Lonza Group, Sartorius AG, BD, Promega, Miltenyi Biotec, Shimadzu, and CellPort Software. These companies drive growth through advanced reagents, single-use systems, and GMP-compliant consumables that support large-scale cell processing and clinical manufacturing. Their strong investment in automation, closed-system workflows, and high-purity media enhances global adoption of cell-based therapies. North America remains the leading region, holding about 39% share in 2024, supported by advanced infrastructure, strong biotech activity, and rapid commercialization of CAR-T and regenerative treatments.

Cell Therapy Consumables Market Insights

• The Cell Therapy Consumables Market reached USD 3439 million in 2024 and is projected to hit USD 7533.31 million by 2032, expanding at a CAGR of 10.3%.
• Strong demand comes from rising adoption of CAR-T, stem-cell, and iPSC therapies, driving higher consumption of media, reagents, and single-use accessories across clinical and commercial workflows.
• Key trends include rapid automation, increased use of closed-system consumables, and growing demand for GMP-grade kits that support precision manufacturing and reduce contamination risks.
• The market features active competition among Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Lonza Group, Sartorius AG, BD, Promega, Miltenyi Biotec, Shimadzu, and CellPort Software, with consumables & accessories leading the segment at about 42% share.
• North America leads with roughly 39% share in 2024, supported by advanced manufacturing capacity and strong biotech funding, while Asia Pacific remains the fastest-growing region due to expanding clinical trials and rising CMO activity.

Cell Therapy Consumables Market Segmentation Analysis:

By Product

Consumables & accessories lead the Cell Therapy Consumables Market with about 42% share in 2024. Strong demand comes from culture media, reagents, cryopreservation kits, and single-use systems used in every therapy workflow. Rising adoption of closed and automated systems boosts repeat purchases and supports steady growth. Raw materials follow due to expansion in upstream processing for viral vectors and engineered cells. Instruments and software gain pace as labs shift toward digital tracking and automated monitoring to meet compliance needs.

• For instance, Lonza’s Cocoon® Platform utilizes single-use cassettes with a working volume of 40 mL, enabling fully closed cell processing without open handling steps.

By Cell Type

T-cells dominate this segment with nearly 48% share in 2024, driven by rapid expansion of CAR-T and TCR-based therapies. Demand rises from scalable activation reagents, transduction kits, and cell expansion consumables. Stem cells hold strong growth potential due to increasing use in regenerative medicine and induced pluripotent stem cell research. Other cell groups, such as NK cells and dendritic cells, continue to gain interest as new immunotherapy platforms advance toward late-stage trials.

• For instance, Miltenyi Biotec’s CliniMACS® Prodigy® system enables automated T-cell activation, transduction, and expansion with documented processing of up to 2 × 10¹⁰ cells in a single manufacturing run.

By End Use

Biopharmaceutical and biotechnology companies hold the largest share at around 55% in 2024 due to continuous investment in cell-based therapy pipelines. High consumption comes from large-scale R&D, GMP production, and commercialization activities. CMOs and CROs expand their adoption as outsourcing rises, especially for vector manufacturing and clinical-grade processing. Other users, including academic institutes and hospitals, show steady demand as translational research and early-stage trials increase worldwide.

Key Growth Drivers

Rising Adoption of Cell-Based Therapies

Growing use of cell-based therapies drives strong demand for cell therapy consumables. Increasing approvals of CAR-T and stem-cell therapies expand the need for high-quality media, reagents, and closed-system consumables. Hospitals and biopharma companies now manage larger treatment volumes, which raises procurement of activation kits, viral vector raw materials, and cryopreservation tools. Expansion of global clinical trials also boosts usage across upstream and downstream processes. As more therapies progress to commercial stages, manufacturers scale production facilities and rely heavily on single-use consumables to meet GMP requirements, ensuring steady growth across core product segments.

• For instance, Novartis’ commercial CAR-T therapy manufacturing network supports multiple centralized sites with individual batch production designed for single-patient dosing, where each treatment requires more than 50 distinct single-use consumables, including sterile tubing sets, culture media bags, and cryogenic storage vials. The process includes controlled cryopreservation at temperatures below -150 °C and validated closed-system handling to maintain product integrity.

Expansion of GMP Manufacturing Capacity

Global investment in GMP manufacturing strengthens the need for compliant consumables. Biopharmaceutical companies and CMOs continue to build advanced gene and cell therapy facilities to support large-scale production. Each facility requires sterile filters, bags, media, aseptic connectors, and traceable reagents designed for regulatory compliance. Rising outsourcing amplifies the need for reliable supply chains and validated consumables to ensure batch consistency. The shift toward automated and closed platforms in GMP suites also increases dependence on high-purity kits and single-use tools. This expansion, supported by government and private funding, creates a strong upward push for consumable-based workflows.

• For instance, Lonza operates multiple dedicated cell and gene therapy manufacturing facilities with cleanroom capacities exceeding 20 individual GMP suites per site, each equipped for closed-system processing. A single GMP suite can consume thousands of sterile single-use components annually, including bioreactor bags up to 2,000 L, validated sterile filters, and pre-assembled tubing manifolds to support multi-batch production.

Increased R&D Investments in Regenerative Medicine

High investment in regenerative medicine supports strong market growth for cell therapy consumables. Stem-cell platforms, iPSC research, and advanced immunotherapies require diverse reagents, culture media, matrices, and disposables for safe expansion and differentiation. Public-private funding accelerates innovation and pushes research labs to scale their consumable usage. Academic institutes and translational centers also adopt next-generation consumables to improve yield, viability, and reproducibility. As regenerative medicine moves toward clinical readiness, researchers depend on optimized kits that reduce contamination risk and support precision manufacturing. These rising R&D activities create sustained, long-term demand.

Key Trends & Opportunities

Shift Toward Automated and Closed-System Workflows

Automation shapes a major opportunity in the Cell Therapy Consumables Market. Labs transition from manual handling to automated units that use standardized single-use consumables. Closed systems help reduce contamination, improve batch quality, and meet stringent GMP norms. This change increases sales of sterile bags, tubes, sensors, media cartridges, and integrated reagent cassettes. Vendors now develop platform-specific consumables that fit automated expansion and isolation systems. As manufacturing volume rises, automated workflows enable higher throughput and reduce labor pressure, creating strong long-term demand for compatible consumables and accessories across research and commercial operations.

• For instance, Miltenyi Biotec’s CliniMACS Prodigy platform integrates cell selection, activation, expansion, and formulation within a single closed system using pre-sterilized tubing sets and reagent cassettes. Each run uses a dedicated single-use set containing over 100 fluidic connections and supports cell processing volumes up to 400 mL, eliminating open handling steps across the full workflow.

Growing Demand for Single-Use and Customizable Consumables

Single-use consumables represent a growing trend as manufacturers aim to avoid cleaning validation and cross-contamination risks. Customizable formats including tailored bags, matrices, scaffolds, pipette tips, and reagent kits gain traction as therapy developers optimize workflows for unique cell lines. Rising demand for flexible, scalable consumables supports vendor opportunities in specialized coating materials, advanced culture surfaces, and cryo-ready formats. This shift also benefits CMOs that require batch-specific consumables for multiple clients. As personalized cell therapy advances, custom and small-lot consumables will remain a core opportunity for innovation and supply expansion.

• For instance, Thermo Fisher Scientific supplies customizable single-use bioprocess containers ranging from 50 mL to 5,000 L for cell therapy manufacturing, with application-specific port configurations and gamma-sterilized materials. These containers are used alongside cryopreservation bags validated for storage below - 150 °C, supporting individualized batch production without reusable hardware.

Key Challenges

High Cost of High-Quality Research and GMP-Grade Consumables

The high cost of GMP-grade consumables remains a major challenge. Manufacturers must meet strict regulatory standards for sterility, purity, and traceability, raising production costs significantly. Developers often require batch-specific or custom consumables, which increases expenses further. Smaller research labs and startups struggle to manage these costs, limiting their ability to scale or advance early-stage therapies. As commercial therapies expand, rising consumable demand strains budgets and increases total manufacturing cost per dose. Achieving price efficiency while maintaining stringent quality standards remains a persistent barrier for buyers and suppliers.

Supply Chain Complexity and Limited Global Manufacturing Capacity

Global supply chain constraints create major challenges for consistent delivery of cell therapy consumables. Many critical materials such as specialized reagents, viral vector raw materials, and sterile single-use plastics depend on limited manufacturers. Disruptions in raw material availability or logistics can slow entire production cycles. High dependence on cold-chain transport further complicates distribution. Regulatory variations across regions delay procurement and extend lead times. As demand grows faster than supply capacity, shortages emerge, impacting both clinical and commercial manufacturing. Strengthening supply resilience and expanding global production remain urgent challenges for the industry.

Regional Analysis

North America

North America leads the Cell Therapy Consumables Market with about 39% share in 2024, driven by strong adoption of CAR-T therapies, advanced GMP facilities, and high R&D spending. The U.S. benefits from a mature biotech sector, well-established clinical trial networks, and rapid expansion of commercial cell therapy manufacturing. Rising investments from biopharma companies and CMOs support wider use of media, reagents, and single-use tools. Canada strengthens growth through funding in stem-cell research and translational centers. Robust regulatory frameworks and expanding production capacity keep the region at the forefront of global demand.

Europe

Europe holds nearly 28% share in 2024, supported by strong pharmaceutical infrastructure and rising investment in regenerative medicine. Countries such as Germany, the U.K., and France lead due to advanced cell therapy manufacturing hubs and supportive regulatory pathways. Demand rises for GMP-grade consumables used in autologous and allogeneic therapy production. Growing academic research and cross-border clinical programs increase consumption of media, reagents, and cryo-solutions. EU funding and collaborative innovation platforms further enhance production capabilities. Expanding clinical adoption and strong CMO presence push Europe toward steady, long-term market growth.

Asia Pacific

Asia Pacific captures about 25% share in 2024 and represents the fastest-growing region. China, Japan, and South Korea drive expansion through rapid investment in cell therapy manufacturing, large patient pools, and government-supported research initiatives. Rising clinical trials, growing CMO capacity, and a shift toward automated workflows increase demand for consumables and accessories. Japan leads in iPSC-based development, boosting procurement of specialized media and matrices. China’s manufacturing ecosystem strengthens supply chains and reduces regional dependency on imports. Expanding biotech ecosystems and lower production costs position Asia Pacific for strong future growth.

Latin America

Latin America accounts for nearly 5% share in 2024, with growth led by Brazil and Mexico. The region experiences rising adoption of regenerative medicine and early-stage cell therapy research programs. Demand increases for basic consumables, culture media, and cryopreservation products used in academic labs and hospital-based trials. Partnerships with North American and European biotech companies help build technical capabilities. Limited GMP infrastructure slows large-scale production, but increasing government funding and private investment support progress. Growing healthcare modernization and expanding research networks create long-term development opportunities for consumable suppliers.

Middle East & Africa

The Middle East & Africa region holds about 3% share in 2024, driven by expanding cell therapy research hubs in the UAE, Saudi Arabia, and South Africa. Growing investment in precision medicine and advanced clinical centers increases demand for reagents, closed-system consumables, and cryogenic tools. Collaborations with global biotech firms support technology transfer and training programs. Limited local manufacturing capacity remains a constraint, but rising healthcare modernization and government-funded innovation projects help accelerate adoption. Expanding regenerative medicine programs position the region for gradual and steady market growth.

Cell Therapy Consumables Market Segmentations:

By Product

• Raw Materials
• Instruments
• Software
• Consumables & Accessories

By Cell Type

• T-cells
• Stem Cells
• Other Cells

By End Use

• Biopharmaceutical & Biotechnology Companies
• CMOs & CROs
• Others

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Competitive Landscape

The Cell Therapy Consumables Market features strong competition led by major players such as Merck KGaA, Promega, Shimadzu, BD, Sartorius AG, CellPort Software, Miltenyi Biotec, Lonza Group, Thermo Fisher Scientific Inc., and Danaher Corporation. These companies compete through advanced consumables, GMP-ready reagents, and single-use systems tailored for cell processing, expansion, and cryopreservation. Leaders invest heavily in automation, digital workflow solutions, and closed-system technologies to support high-throughput manufacturing. Partnerships with CMOs, biotech firms, and academic centers strengthen product reach and accelerate innovation. Many players also expand regional facilities to safeguard supply chains and meet increasing global demand. Continuous development of specialized media, viral vector reagents, and regulatory-compliant consumables keeps competition intense and drives product differentiation across the industry.

Key Player Analysis

• Merck KGaA
• Promega
• Shimadzu
• BD
• Sartorius AG
• CellPort Software
• Miltenyi Biotec
• Lonza Group
• Thermo Fisher Scientific Inc.
• Danaher Corporation

Recent Developments

• In October 2025, Promega entered a strategic partnership with MilliporeSigma to co-develop 3D cell drug discovery assays. The collaboration combines organoid models with Promega reporter assays for real-time cell activity tracking. This strengthens Promega’s assay consumables used in advanced cell models for cell and gene therapy research.
• In September 2025, Sartorius AG expanded its Illkirch site to add GMP production of transfection reagents. The enlarged facility now supplies pharmaceutical-grade reagents critical for viral vector manufacturing. These raw materials are key consumables for scalable cell and gene therapy production worldwide.
• In October 2024, BD introduced robotics-compatible BD OMICS-One XT reagent kits with Hamilton’s NGS STAR platform. The solution automates single-cell library preparation and multiomics studies at high throughput. These automation-ready reagents enhance reproducible cell analysis that underpins cell therapy discovery and process development.

Report Coverage

The research report offers an in-depth analysis based on Product, Cell Type, End-Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. Demand for consumables will rise as more cell therapies progress from trials to commercial use.
2. Automation and closed-system workflows will gain wider adoption across manufacturing sites.
3. Single-use consumables will become standard to reduce contamination risks and support GMP compliance.
4. Customizable media, matrices, and reagent kits will expand to meet therapy-specific needs.
5. CMOs and CROs will increase procurement as outsourcing of cell therapy production grows.
6. AI-driven analytics and digital tracking tools will improve batch consistency and consumable planning.
7. Stem-cell and iPSC platforms will drive higher demand for specialized culture and differentiation products.
8. Global supply chains will expand through new regional manufacturing hubs for critical consumables.
9. Sustainability initiatives will push manufacturers to adopt eco-friendly and recyclable single-use options.
10. Collaboration between biopharma companies and technology providers will accelerate innovation in advanced consumable formats.